Back to Newsroom

Cempra to Present Data at ICAAC on Solithromycin’s (CEM-101) Activity Against a Broad Range of Pathogens

CHAPEL HILL, N.C., Sept. 10, 2013 — Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing differentiated antibiotics to meet critical medical needs in the treatment of bacterial infections, today announced that it will present data at the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Denver, Colorado, showing the marked activity of solithromycin against a broad range of pathogens including four proposed or designated by the Food and Drug Administration (FDA) as qualified infectious disease pathogens (QIDP) under the Generating Antibiotic Incentives Now (GAIN) Act.